Registration Strip Icon for alerts Inscrivez-vous pour des alertes en temps réel, un portefeuille personnalisé et des mouvements de marché.

TEVA

Teva Pharmaceutical Indu... (TEVA)

Teva Pharmaceutical Industries Ltd
De:
Trier par:
 Showing the most relevant articles for your search:NYSE:TEVA
DateHeureSourceTitreSymboleSociété
07/02/202216h12Business WireTeva Reaches Agreement With Texas to Settle the State’s Opioid-Related ClaimsNYSE:TEVATeva Pharmaceutical Industries Ltd
01/02/202214h00Business WireResearch Finds COVID Pandemic Worsened Health Equity GapNYSE:TEVATeva Pharmaceutical Industries Ltd
19/01/202213h11TipRanksTeva to Pay $420M to Settle Shareholders’ Generic Drug Pricing Lawsuit — ReportNYSE:TEVATeva Pharmaceutical Industries Ltd
18/01/202214h00Business WireTeva to Host Conference Call to Discuss Fourth Quarter and Full Year 2021 Financial Results and 2022 Financial Guidance at 8 a.m. ET on February 9, 2022NYSE:TEVATeva Pharmaceutical Industries Ltd
04/01/202219h35Business WireTeva to Present at the 40th Annual J.P. Morgan Healthcare ConferenceNYSE:TEVATeva Pharmaceutical Industries Ltd
31/12/202117h06TipRanksTeva Found Guilty of Fueling New York Opioid CrisisNYSE:TEVATeva Pharmaceutical Industries Ltd
30/12/202119h29Business WireTeva Statement Following New York Jury Ruling in Opioids TrialNYSE:TEVATeva Pharmaceutical Industries Ltd
30/12/202119h05Dow Jones NewsTeva Fueled Opioid Addiction in New York, Jury Finds -- ReutersNYSE:TEVATeva Pharmaceutical Industries Ltd
29/12/202109h27TipRanksTeva Long-Term Prospects Bright, Despite HeadwindsNYSE:TEVATeva Pharmaceutical Industries Ltd
27/12/202110h11TipRanksTeva Partners with Tikun Olam-Cannbit to Sell Medical Cannabis Products – ReportNYSE:TEVATeva Pharmaceutical Industries Ltd
23/12/202114h54TipRanksTeva Launches First Generic of Naloxone Hydrochloride Nasal Spray in the U.S.NYSE:TEVATeva Pharmaceutical Industries Ltd
22/12/202122h30Business WireTeva Announces Launch of First-to-Market Generic Version of Narcan® (Naloxone Hydrochloride Nasal Spray), in the U.S.NYSE:TEVATeva Pharmaceutical Industries Ltd
06/12/202115h43Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NYSE:TEVATeva Pharmaceutical Industries Ltd
01/12/202114h00Business WireTeva Announces Launch of an Authorized Generic of Epiduo® Forte Gel (adapalene and benzoyl peroxide gel 0.3%/2.5%), in the U.S.NYSE:TEVATeva Pharmaceutical Industries Ltd
25/11/202118h00GlobeNewswire Inc.Quantum Genomics signs an exclusive license agreement with Teva Israel Ltd.NYSE:TEVATeva Pharmaceutical Industries Ltd
24/11/202113h51Edgar (US Regulatory)Current Report Filing (8-k)NYSE:TEVATeva Pharmaceutical Industries Ltd
10/11/202115h17Business WireTeva Announces Early Tender Results of its Debt Tender Offer, Increase of the Maximum Tender Amount and Election of Early SettlementNYSE:TEVATeva Pharmaceutical Industries Ltd
09/11/202111h56Business WireVon der Effektivität im Rahmen klinischer Versuchsreihen zur tatsächlichen Wirksamkeit - erste Daten zu AJOVY® ▼ (Fremanezumab) aus dem European Real World Evidence ProgrammNYSE:TEVATeva Pharmaceutical Industries Ltd
09/11/202111h54Business WireDe l'efficacité clinique à l'efficacité en monde réel : les premières données AJOVY® ▼ ▼ (frémanezumab) du programme European Real World EvidenceNYSE:TEVATeva Pharmaceutical Industries Ltd
08/11/202122h02Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:TEVATeva Pharmaceutical Industries Ltd
08/11/202110h25Business WireFrom Clinical Trial Efficacy to Real-World Effectiveness First AJOVY® ▼ (fremanezumab) Data from European Real World Evidence ProgramNYSE:TEVATeva Pharmaceutical Industries Ltd
04/11/202121h43Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NYSE:TEVATeva Pharmaceutical Industries Ltd
03/11/202111h00Business WireTeva Becomes First Pharmaceutical Company to Execute Sustainability-linked Bond Tied to both Climate and Access to Medicine TargetsNYSE:TEVATeva Pharmaceutical Industries Ltd
02/11/202122h31Business WireTeva Announces Successful Upsize of Sustainability-Linked Senior Notes Offering and Pricing of $5,000,000,000 of Sustainability-Linked Senior NotesNYSE:TEVATeva Pharmaceutical Industries Ltd
02/11/202122h30Edgar (US Regulatory)Free Writing Prospectus - Filing Under Securities Act Rules 163/433 (fwp)NYSE:TEVATeva Pharmaceutical Industries Ltd
02/11/202103h00Business WireCalifornia Judge Rules That Teva Did Not Cause a Public Nuisance or Make False or Misleading Statements About OpioidsNYSE:TEVATeva Pharmaceutical Industries Ltd
30/10/202122h00Business WireNew Phase 3 Data Presented at Psych Congress 2021 Showed TV-46000/mdc-IRM Significantly Prolonged Time to Impending Relapse Compared to Placebo in Patients with SchizophreniaNYSE:TEVATeva Pharmaceutical Industries Ltd
27/10/202114h52Edgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(3) (424b3)NYSE:TEVATeva Pharmaceutical Industries Ltd
27/10/202113h15Business WireTeva Announces Launch of $4,000,000,000 Offering of Sustainability-linked Senior NotesNYSE:TEVATeva Pharmaceutical Industries Ltd
27/10/202113h15Business WireTeva Announces $3,500,000,000 Debt Tender Offers for Notes Due 2022-2024NYSE:TEVATeva Pharmaceutical Industries Ltd
 Showing the most relevant articles for your search:NYSE:TEVA